To assess the clinical applicability of ctDNA testing before therapy assignment, Schwaederlé et al. analyzed plasma ctDNA in 88 consecutive NSCLC patients and found that ALK ranked among the most frequently mutated genes (6.8% of patients), with a high concordance rate between ctDNA and tissue testing (Table 1). Here, ALK is linked to non-small cell lung carcinoma.